Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Veklury Use in Mild COVID-19 Could Be Considered: MHLW
January 31, 2022
- MSD Moves Up Supply of 50000 Courses of Lagevrio to Japan
January 31, 2022
- Cost-Effectiveness Analysis Temporarily Halted for Zolgensma to Collect Long-Term Data
January 31, 2022
- MHLW Panel OKs Mix-and-Match HPV Vaccines in “Catch-Up” Program
January 31, 2022
- MHLW Council Deems Public Knowledge-Based Filings Acceptable for 8 Fertility Treatment Indications
January 28, 2022
- MHLW Sets Volume Thresholds for Drug Orders to Resolve Generic Shortages
January 28, 2022
- Japan Panel Agrees to Vaccinate Children under Free COVID-19 Inoculation Program
January 27, 2022
- Up to 3 Refills Permitted per Prescription, No Refilling for Drugs with Dosage Restrictions: Chuikyo
January 27, 2022
- Drug Pricing Rules to Be Applied to BMS’ CAR-T Therapy Abecma: Chuikyo
January 27, 2022
- PMDA to Place Top Priority on Safety Measures under Proposed Emergency Approval System: Chief Executive
January 25, 2022
- Lagevrio Should Not Be Given to Asymptomatic COVID Patients: MHLW
January 25, 2022
- Japan to Import Pfizer’s Pediatric Vaccine Next Month, Inoculations to Begin in March: Minister
January 25, 2022
- MHLW Panel Backs Wholesaler Data Use to Monitor Vaccine Shortages in Public Programs
January 25, 2022
- Providing Info on Investigational Drugs on Company Websites Violates PMD Law: MHLW
January 25, 2022
- Lilly’s Retevmo Up for PAFSC Review for Thyroid Cancer on Feb. 4; Lenvima-Keytruda Combo on Agenda for RCC
January 24, 2022
- No Major Safety Concerns for COVID-19 Jabs: MHLW Panels
January 24, 2022
- Promote Both Pfizer/Moderna Vaccines for Boosters: Health Minister
January 24, 2022
- Veklury Allowed for Administration in Homebound Patients
January 24, 2022
- JPMA Calls for Data Consolidation under Medical Infrastructure Law: Govt Hearing
January 24, 2022
- MHLW Approves Lilly’s Migrane Drug Reyvow, Amgen’s KRAS Inhibitor and More
January 21, 2022
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…